Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Pediatric Endocrinology and Metabolism

Editor-in-Chief: Kiess, Wieland

Ed. by Bereket, Abdullah / Darendeliler, Feyza / Dattani, Mehul / Gustafsson, Jan / Luo, Fei Hong / Mericq, Veronica / Toppari, Jorma

IMPACT FACTOR 2018: 1.239

CiteScore 2018: 1.22

SCImago Journal Rank (SJR) 2018: 0.507
Source Normalized Impact per Paper (SNIP) 2018: 0.562

See all formats and pricing
More options …
Ahead of print


Providing quality care for children and adolescents with diabetes from lower-income families in Mexico

María Elena Mota-Oropeza / Hannah Elizabeth Bartley
  • Life for a Child Program, Diabetes NSW & ACT, Glebe, NSW, Australia
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Norma Daniela Hernández-Pérez / Arely Gutiérrez Lara / Nancy Alejandra Vázquez-López / Maria Francisa Flores / Mariana Marroquín Velázquez / Maria José Castañeda-Saldivar / Angela Christine Middlehurst / Alicia Josephine Jenkins / Graham David Ogle
  • Corresponding author
  • Life for a Child Program, Diabetes NSW & ACT, Glebe, NSW, Australia
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-09-04 | DOI: https://doi.org/10.1515/jpem-2019-0363



The objective of this study was to determine the demographic and clinical features of youth supported by member associations of the Federación Mexicana de Diabetes and the Life for a Child Program (LFAC).


An analysis of 2017 Annual Clinical Data Sheets of 306 subjects from five Mexican centers was performed.


Type 1 diabetes (T1D) was diagnosed in 292 subjects; 54.6% were female, with six diagnosed aged <6 months (genetic tests not yet conducted). Type 2 diabetes (T2D) or other types were diagnosed in 11 and three subjects, respectively. T1D diagnosis age ranged 0.0–22.6 years with a peak at 8 years. The mean ± standard deviation (SD) diabetes duration was 5.3 ± 3.5 years (range 0.0–21.0 years), with a mean ± SD subject age at check-up of 13.3 ± 4.3 years. Of the T1D subjects, 1.0%, 6.7%, 13.7% and 78.6% were receiving 1, 2, 3 and ≥4 insulin injections/day with a mean ± SD daily dose of 0.92 ± 0.34 U/kg. The median number of blood glucose tests/week was 40. The mean/median hemoglobin A1c (HbA1c) levels for those with duration ≥6 months were 8.7/8.4% (72/68 mmol/mol) and were higher in adolescents vs. children. Elevated body mass index SD, triglycerides (≥150 mg/dL) and non-high-density lipoprotein (HDL)-cholesterol (≥130 mg/dL) were common: 7.6%, 11.0% and 12.7% (n = 288, 218 and 180, respectively). Serum creatinine levels were normal in all tested subjects (n = 194).


Youth with diabetes in less-resourced families in Mexico are achieving reasonable glycemia. Most T1D patients use a basal bolus insulin regimen and test blood glucose several times daily. Some subjects have adverse vascular risk factor profiles. Further attention is needed to prevent chronic complications. Monogenic diabetes is very likely in some youth, and genetic testing is indicated.

Keywords: adolescents; children; diabetes; HbA1c; lipids; Mexico


  • 1.

    Ogle GD, Middlehurst AC, Silink M. The IDF Life for a Child Program Index of diabetes care for children and youth. Pediatr Diabetes. 2016;17:374–84.CrossrefWeb of SciencePubMedGoogle Scholar

  • 2.

    Ogle GD, Kim H, Middlehurst AC, Silink M, Jenkins AJ. Financial costs for families of children with Type 1 diabetes in lower-income countries. Diabet Med 2016;33:820–6.CrossrefPubMedGoogle Scholar

  • 3.

    Life for a Child Program [Internet]. [cited 2018 Nov 8]. https://www.lfacinternationall.org.

  • 4.

    World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF Consultation, Geneva, 2006.Google Scholar

  • 5.

    World Health Organization. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: WHO; 2006 [Internet]. http://hpps.kbsplit.hr/hpps-2008/pdf/dok03.pdf.

  • 6.

    de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007;85:660–7.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 7.

    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(Suppl 2):555–76.PubMedGoogle Scholar

  • 8.

    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604–12.CrossrefWeb of SciencePubMedGoogle Scholar

  • 9.

    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.PubMedGoogle Scholar

  • 10.

    DiMeglio LA, Carlo LA, Ethel C, Maria EC, Sabine E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes 2018;19:105–14.Web of ScienceCrossrefGoogle Scholar

  • 11.

    Gómez-Díaz RA, Peŕez-Pérez G, Hernańdez-Cuesta IT, Rodriǵuez-García JD, Guerrero-López R, et al. Incidence of type 1 diabetes in Mexico: data from an institutional register 2000–2010. Diabetes Care 2012;35:e77.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 12.

    TD1 Exchange [Internet]. [cited 2018 Sep 6]. www.t1dexchange.org.

  • 13.

    Donaghue K, Wadwa R, Dimeglio L, Wong T, Chiarelli F, et al. Pediatric Diabetes ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes 2014;15:257–69.Google Scholar

  • 14.

    Shah AS, Maahs DM, Stafford JM, Dolan LM, Lang W, et al. Predictors of dyslipidemia over time in youth with type 1 diabetes: for the SEARCH for Diabetes in Youth study. Diabetes Care 2017;40:607–13.Web of SciencePubMedCrossrefGoogle Scholar

  • 15.

    Donaghue KC, Marcovecchio L, Wadwa RP, Chew EY, Wong T. ISPAD Clinical Practice Consensus Guidelines 2018: microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes 2018;27:262–74.Web of ScienceGoogle Scholar

  • 16.

    International Diabetes Federation. IDF Diabetes Atlas. 2017.Google Scholar

  • 17.

    Altamirano-Bustamante N, Islas-Ortega L, Robles-Valdes C, Garduno-Espinosa J, Morales-Cisneros G, et al. Economic family burden of metabolic control in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2008;21:1163–8.PubMedGoogle Scholar

  • 18.

    Klatman EL, Jenkins AJ, Ahmedani MY, Ogle GD. Blood glucose meters and test strips: global market and challenges to access in low-resource settings. Lancet Diabetes Endocrinol 2019;7:150–60.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 19.

    Hernandez-Cordero S, Cuevas-Nasu L, Moran-Ruan MC, Mendez-Gomez Humaran I, Avila-Arcos MA, et al. Overweight and obesity in Mexican children and adolescents during the last 25 years. Nutr Diabetes 2017;7:e247.Web of SciencePubMedCrossrefGoogle Scholar

  • 20.

    Clements MA, Foster NC, Maahs DM, Schatz DA, Olson BA, et al. Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult participants in the T1D exchange clinic registry. Pediatr Diabetes 2016;17:327–36.Web of ScienceCrossrefGoogle Scholar

  • 21.

    Faradji R, Valenzuela-Lara M, Diaz-Barriga MAP, Ferreira ACA, Bustamante MJF, et al. Results of the multi-centric RENACED Diabetes Type 1 in Mexico. In: The Official Journal of the ATTD, 2018 Conference abstracts; 2018. p. 092.Google Scholar

  • 22.

    McKnight JA, Wild SH, Lamb MJ, Cooper MN, Jones TW, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 2015;32:1036–50.PubMedCrossrefGoogle Scholar

  • 23.

    Witsch M, Kosteria I, Kordonouri O, Alonso G, Archinkova M, et al. Possibilities and challenges of a large international benchmarking in pediatric diabetology – the SWEET experience. Pediatr Diabetes 2016;17:7–15.CrossrefWeb of SciencePubMedGoogle Scholar

  • 24.

    Ogle GD, von Oettingen JE, Middlehurst AC, Hanas R, Orchard TJ. Levels of type 1 diabetes care in children and adolescents for countries at varying resource levels. Pediatr Diabetes 2019;20:93–8.Web of SciencePubMedGoogle Scholar

  • 25.

    Evia-Viscarra ML, Guardado-Mendoza R, Rodea-Montero ER. Clinical and metabolic characteristics among Mexican children with different types of diabetes mellitus. PLoS One 2016;11:e0168377.Web of SciencePubMedCrossrefGoogle Scholar

  • 26.

    Rubio-Cabezas O, Hattersley AT, Njolstad PR, Mlynarski W, Ellard S, et al. ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2014;15(Suppl 2):47–64.PubMedGoogle Scholar

  • 27.

    Jenkins AJ, Best JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 2004;20:349–68.PubMedCrossrefGoogle Scholar

  • 28.

    Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, et al. Lipoproteins and diabetic microvascular complications. Curr Pharm Des 2004;10:3395–418.PubMedCrossrefGoogle Scholar

  • 29.

    Lyons TJ, Jenkins AJ. Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 1997;8:174–80.PubMedCrossrefGoogle Scholar

  • 30.

    Medina-Bravo P, Medina-Urrutia A, Juárez-Rojas JG, Cardoso-Saldaña G, Jorge-Galarza E, et al. Glycemic control and high-density lipoprotein characteristics in adolescents with type 1 diabetes. Pediatr Diabetes 2013;14:399–406.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 31.

    Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (London, England) 2008;371:117–25.CrossrefPubMedGoogle Scholar

About the article

Corresponding author: Adj. Professor Graham David Ogle, Life for a Child Program, Diabetes NSW & ACT, Glebe, NSW 2037, Australia; and NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW 2006, Australia, Phone: +61 400 683 574

aCo-First Authors.

Received: 2019-08-07

Accepted: 2019-08-08

Published Online: 2019-09-04

Author contributions: MEMO collected the data and contributed to the manuscript; NAVL, MMV, FFR, DHP and AGL collected data and assisted with confirming patient information; HB analyzed the data and co-wrote the manuscript; AM assisted in data analysis and contributed to the manuscript; AJ helped with interpretation of the data and contributed to the manuscript; GO designed the study and co-wrote the manuscript.

Research funding: This work was supported by the Leona M and Harry B Helmsley Charitable Trust. HB was partly funded by a University of Sydney Summer Research Scholarship. AJJ is funded by a NHMRC (Australia) Practitioner Fellowship and is a Sydney Medical School Foundation Fellow.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Conflict of interest statement: None of the authors have any conflicts of interest with respect to this study.

Institutional review board statement: The study was reviewed and approved by the Federación Mexicana de Diabetes, A.C.

Data sharing statement: Not relevant.

Citation Information: Journal of Pediatric Endocrinology and Metabolism, 20190363, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: https://doi.org/10.1515/jpem-2019-0363.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in